Amgen, Cytokinetics and Servier have announced that their Phase III GALACTIC-HF clinical trial of heart failure drug, omecamtiv mecarbil, passed an interim futility analysis.

Futility evaluation is conducted to check if the trial would demonstrate a positive outcome, and could result in trials being halted early.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A Data Monitoring Committee (DMC) reviewed GALACTIC-HF data and recommended that the trial could continue without any changes.

The trial would have been suspended if the data showed a low chance of a clinically meaningful and statistically significant benefit on the primary endpoint with omecamtiv mecarbil plus standard of care, compared to placebo plus standard of care.

“GALACTIC-HF is being conducted to assess the ability of the drug and standard of care combination to decrease the risk of heart failure events and cardiovascular (CV) death.”

Omecamtiv mecarbil is a selective cardiac myosin activator designed to bind to the catalytic domain of myosin, which plays a key role in the process of cardiac contraction.

It is intended to potentially treat heart failure with reduced ejection fraction (HFrEF). The drug is being co-developed by Amgen and Cytokinetics, with funding support from Servier.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GALACTIC-HF is being conducted to assess the ability of the drug and standard of care combination to decrease the risk of heart failure events and cardiovascular (CV) death in patients with chronic HFrEF.

The trial commenced enrolment in 2016 and is set to enrol about 8,000 subjects in more than 35 countries. More than 7,000 patients have already been recruited and the trail is expected to reach its target in the first half of this year.

Last month, the partners started enrolment in another Phase III trial called METEORIC-HF to assess omecamtiv mecarbil for the treatment of HFrEF.

This trial is designed to monitor the drug’s effect on exercise capacity, compared to placebo.